The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Maksim V. Baranov; Frans Bianchi; Geert van den Bogaart

doi:10.3390/cells10010030

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Maksim V. Baranov, Frans Bianchi, Geert van den Bogaart^*

^*Corresponding author for this work

Molecular Immunology & Microbiology

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

69 Downloads (Pure)

Abstract

The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

Original language	English
Article number	30
Number of pages	5
Journal	Cells
Volume	10
Issue number	1
DOIs	https://doi.org/10.3390/cells10010030
Publication status	Published - Jan-2021

Keywords

SARS-CoV-2
COVID-19
apilimod
LAM-002A
STA-5326
PIKfyve

Access to Document

10.3390/cells10010030Licence: CC BY

The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19 Final publisher's version, 765 KBLicence: CC BY

Handle.net

Persistent link

Cite this

@article{76ea4d5ab070477989222709dba74ea2,

title = "The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19",

abstract = "The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.",

keywords = "SARS-CoV-2, COVID-19, apilimod, LAM-002A, STA-5326, PIKfyve",

author = "Baranov, {Maksim V.} and Frans Bianchi and {van den Bogaart}, Geert",

year = "2021",

month = jan,

doi = "10.3390/cells10010030",

language = "English",

volume = "10",

journal = "Cells",

issn = "2073-4409",

publisher = "MDPI AG",

number = "1",

}

TY - JOUR

T1 - The PIKfyve Inhibitor Apilimod

T2 - A Double-Edged Sword against COVID-19

AU - Baranov, Maksim V.

AU - Bianchi, Frans

AU - van den Bogaart, Geert

PY - 2021/1

Y1 - 2021/1

N2 - The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

AB - The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

KW - SARS-CoV-2

KW - COVID-19

KW - apilimod

KW - LAM-002A

KW - STA-5326

KW - PIKfyve

U2 - 10.3390/cells10010030

DO - 10.3390/cells10010030

M3 - Article

SN - 2073-4409

VL - 10

JO - Cells

JF - Cells

IS - 1

M1 - 30

ER -